Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
524 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05100316 | Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials | terminated | Phase 2 | 16 | GlaxoSmithKlineINDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin | terminated | Phase 3 | 16 | GlaxoSmithKlineINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02992743 |
| Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma |
| completed |
| Phase 2 |
| 23 |
| GlaxoSmithKlineINDUSTRY |
| 1 |
| Apr 11, 2023 |
| clinicaltrials |
| NCT03614728 | Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 2 | Feb 6, 2023 | clinicaltrials |
| NCT05553808 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1 | completed | Phase 2 | 105 | GlaxoSmithKlineINDUSTRY | 12 | Jan 19, 2023 | clinicaltrials |
| NCT03150056 | Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer | terminated | Phase 1 | 73 | GlaxoSmithKlineINDUSTRY | 4 | Aug 10, 2022 | clinicaltrials |
| NCT03666988 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 1 | 31 | GlaxoSmithKlineINDUSTRY | 4 | May 20, 2022 | clinicaltrials |
| NCT02224456 | Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis | completed | Phase 4 | 197 | GlaxoSmithKlineINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03168438 | Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | terminated | Phase 1 | 6 | GlaxoSmithKlineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03438006 | A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects | completed | — | 3,016 | GlaxoSmithKlineINDUSTRY | 1 | Sep 8, 2021 | clinicaltrials |
| NCT02588612 | Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 10 | GlaxoSmithKlineINDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT03351140 | Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 1 | Jul 14, 2021 | clinicaltrials |
| NCT01343043 | A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma(NY-ESO-1) | completed | Phase 1 | 50 | GlaxoSmithKlineINDUSTRY | 1 | Jun 30, 2021 | clinicaltrials |
| NCT01220128 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer(INDUCT) | terminated | Phase 2 | 66 | GlaxoSmithKlineINDUSTRY | 7 | May 25, 2021 | clinicaltrials |
| NCT02528357 | GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1) | completed | Phase 1 | 141 | GlaxoSmithKlineINDUSTRY | 4 | May 18, 2021 | clinicaltrials |
| NCT01798056 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy | completed | Phase 3 | 237 | GlaxoSmithKlineINDUSTRY | 6 | May 13, 2021 | clinicaltrials |
| NCT00896480 | Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma | completed | Phase 2 | 24 | GlaxoSmithKlineINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | terminated | Phase 3 | 1,351 | GlaxoSmithKlineINDUSTRY | 32 | Mar 5, 2021 | clinicaltrials |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | terminated | Phase 3 | 2,278 | GlaxoSmithKlineINDUSTRY | 34 | Dec 22, 2020 | clinicaltrials |
| NCT00942162 | A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma(PREDICT) | completed | Phase 2 | 125 | GlaxoSmithKlineINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT02798978 | A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects | completed | Phase 1 | 42 | GlaxoSmithKlineINDUSTRY | 1 | Nov 27, 2020 | clinicaltrials |
| NCT01149343 | Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | completed | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 6 | Nov 20, 2020 | clinicaltrials |
| NCT00481767 | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age. | completed | Phase 3 | 676 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2020 | clinicaltrials |
| NCT02706535 | A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential | completed | Phase 1 | 29 | GlaxoSmithKlineINDUSTRY | 1 | Nov 16, 2020 | clinicaltrials |
| NCT00947115 | Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects | completed | Phase 3 | 525 | GlaxoSmithKlineINDUSTRY | 2 | Oct 30, 2020 | clinicaltrials |
| NCT02215096 | Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 37 | GlaxoSmithKlineINDUSTRY | 2 | Oct 22, 2020 | clinicaltrials |
| NCT00706238 | MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma | terminated | Phase 2 | 5 | GlaxoSmithKlineINDUSTRY | 3 | Oct 8, 2020 | clinicaltrials |
| NCT02064387 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 | completed | Phase 1 | 79 | GlaxoSmithKlineINDUSTRY | 3 | Aug 11, 2020 | clinicaltrials |
| NCT03681951 | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | terminated | Phase 2 | 8 | GlaxoSmithKlineINDUSTRY | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01031069 | Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females | completed | Phase 4 | 873 | GlaxoSmithKlineINDUSTRY | 4 | Jul 21, 2020 | clinicaltrials |
| NCT01381575 | Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls | completed | Phase 3 | 1,447 | GlaxoSmithKlineINDUSTRY | 5 | Jun 9, 2020 | clinicaltrials |
| NCT03702036 | Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma | no longer available | — | — | GlaxoSmithKlineINDUSTRY | 0 | Apr 13, 2020 | clinicaltrials |
| NCT01627561 | Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old | completed | Phase 3 | 148 | GlaxoSmithKlineINDUSTRY | 3 | Apr 10, 2020 | clinicaltrials |
| NCT01587703 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | completed | Phase 1 | 196 | GlaxoSmithKlineINDUSTRY | 7 | Mar 16, 2020 | clinicaltrials |
| NCT02630251 | Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors | terminated | Phase 1 | 5 | GlaxoSmithKlineINDUSTRY | 1 | Feb 12, 2020 | clinicaltrials |
| NCT00877877 | Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects. | completed | Phase 3 | 632 | GlaxoSmithKlineINDUSTRY | 5 | Jan 18, 2020 | clinicaltrials |
| NCT00586339 | Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females | completed | Phase 2 | 150 | GlaxoSmithKlineINDUSTRY | 1 | Jan 3, 2020 | clinicaltrials |
| NCT00637195 | Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) | completed | Phase 3 | 152 | GlaxoSmithKlineINDUSTRY | 1 | Jan 3, 2020 | clinicaltrials |
| NCT00250276 | Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. | completed | Phase 3 | 798 | GlaxoSmithKlineINDUSTRY | 3 | Jan 2, 2020 | clinicaltrials |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery | completed | Phase 2 | 182 | GlaxoSmithKlineINDUSTRY | 14 | Jan 2, 2020 | clinicaltrials |
| NCT00294047 | Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older | completed | Phase 3 | 5,752 | GlaxoSmithKlineINDUSTRY | 12 | Jan 2, 2020 | clinicaltrials |
| NCT00359619 | Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine | completed | Phase 2 | 383 | GlaxoSmithKlineINDUSTRY | 2 | Jan 2, 2020 | clinicaltrials |
| NCT00423046 | Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age | completed | Phase 3 | 1,106 | GlaxoSmithKlineINDUSTRY | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00140738 | Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer | completed | Phase 1 | 3 | GlaxoSmithKlineINDUSTRY | 5 | Dec 27, 2019 | clinicaltrials |
| NCT00231413 | Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine. | completed | Phase 2 | 383 | GlaxoSmithKlineINDUSTRY | 2 | Dec 12, 2019 | clinicaltrials |
| NCT00196937 | Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 | completed | Phase 3 | 667 | GlaxoSmithKlineINDUSTRY | 2 | Dec 11, 2019 | clinicaltrials |
| NCT02034123 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | terminated | Phase 1 | 29 | GlaxoSmithKlineINDUSTRY | 3 | Dec 6, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials